Another Win For Novo Nordisk (NOVO)

The National Health Service in England is rolling out the weight-loss drug Wegovy, signalling a shift toward using GLP-1 treatments to prevent serious cardiovascular events. Clinical data shows the drug, which contains semaglutide, can significantly reduce the risk of heart attacks and strokes in high-risk patients, extending its value far beyond weight loss and diabetes treatments. For Novo Nordisk, the decision reinforces Wegovy’s position as a long-term, high-demand therapy within public healthcare systems, supporting sustained revenue growth.

Source: